Fig. 2: Tumour response was assessed by the investigator per RECIST v1.1. | Nature Communications

Fig. 2: Tumour response was assessed by the investigator per RECIST v1.1.

From: Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial

Fig. 2: Tumour response was assessed by the investigator per RECIST v1.1.

Maximal change in tumour size from baseline in target (A) non-irradiated lesion(s) and (B) irradiated lesion(s) (n = 21, patients with baseline and at least one post-treatment radiographic evaluation). Pentagrams denoted patients with PD based on new lesion(s) or progression of non-target lesion(s). Each bar represents an individual patient’s response, with colours indicating the response group. C Event-history plots of the treatment strategies of enrolled patients. Time zero is the start of the SBRT treatment. D Kaplan–Meier curves of (upper) progression-free survival (PFS) and (lower) overall survival (OS) in patients (n = 21). Change of individual tumour burden regarding the non-irradiated lesion(s) (E) and irradiated lesion(s) (F) over time from baseline. BOR, best overall response. PR, partial response. CR, complete response. SD, stable disease. PD, progressive disease. Source data were provided as a Source Data file.

Back to article page